What is CIBINQO used for?

1 INDICATIONS AND USAGE CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. CIBINQO is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-se

How does CIBINQO work?

11 DESCRIPTION CIBINQO (abrocitinib) tablets contain the free base of abrocitinib, a Janus kinase (JAK) inhibitor, for oral administration.

What pharmaceutical form is CIBINQO available in?

CIBINQO: Tabletki powlekane 50 mg (doustna)

Is CIBINQO OTC or prescription only?

CIBINQO requires a doctor's prescription.

What are the side effects of CIBINQO?

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Serious Infections [see Warnings and Precautions (5.1) ] • Mortality [see Warnings and Precautions (5.2) ] • Malignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3) ] • Major Adverse Cardiovascular Events [see Warnings and Precautions (5.4) ] • Thrombosis [see Warnings and Precautions (5.5) ] • Laboratory Abnormalities [see Warnings and Precautions (5.6)

Who should NOT take CIBINQO?

4 CONTRAINDICATIONS CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.6) , Drug Interactions (7.2) , and Clinical Pharmacology (12.2) ]. Antiplatelet therapies except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment. ( 4 )

Does CIBINQO interact with other medications?

7 DRUG INTERACTIONS • Strong inhibitors of CYP2C19: The recommended dosage is 50 mg once daily or 100 mg once daily for those patients who are not responding to 50 mg once daily. ( 2.5 , 7.1 ) • Moderate to strong inhibitors of both CYP2C19 and CYP2C9, or strong CYP2C19 or CYP2C9 inducers: Avoid concomitant use. ( 7.1 ) • P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities: Monitor or titrate dosage of P-gp substrate. ( 7.2 ) 7.1

Can CIBINQO be used during pregnancy?

8 USE IN SPECIFIC POPULATIONS • Lactation : Breastfeeding not recommended. ( 8.2 ) • Renal Impairment : Avoid use in patients with severe renal impairment or end-stage renal disease. ( 8.6 ) • Hepatic Impairment : Avoid use in patients with severe hepatic impairment. ( 8.7 ) 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health c

What precautions should be taken with CIBINQO?

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

What ATC class does CIBINQO belong to?

CIBINQO: ATC D11AH08. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

CIBINQO

50 mg, Tabletki powlekane

INN: Abrocitinibum

Data updated: 2026-04-13

Available in:

🇨🇿🇩🇪🇬🇧🇪🇸🇫🇷🇵🇱🇵🇹🇸🇰🇺🇦

Form

Tabletki powlekane

Dosage

50 mg

Route

doustna

Storage

Store CIBINQO at 20°C to 25°C (68°F to 77°F), excursions pe‍‍‍‍‍‍‍rmitted between 15°C to 30°C (59°F to 86°F). Keep in original package. The container closure system is child resistant.

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.